Homepage Top Section2

The new line, representing an investment of nearly €6.6m ($7.1m), is located at the Life Science Center in Nantong. This development is aimed at meeting the increasing local

SPS is a rare, debilitating neurological autoimmune disorder characterised by muscle stiffness and spasms. Kyverna’s KYV-101 is an autologous, fully human CD19 CAR T-cell therapy designed to address

The deal, which was announced in May 2024, includes an upfront cash payment of $1.3bn and $1.7bn in milestone payments on meeting developmental, regulatory and commercial goals. Under

The approval of Leqembi (generic name: Lecanemab) in Israel marks a significant milestone, as Israel becomes the sixth territory to endorse the drug for Alzheimer’s treatment after the

Ambien CR (zolpidem tartrate extended-release tablets) is intended for the short-term management of insomnia, which is manifested by challenges in initiating sleep and/or maintaining sleep continuity. Ambien (zolpidem

This product different from other versions of fosaprepitant as it is free from Polysorbate 80 and requires no reconstitution or dilution, simplifying administration directly from the vial utilising

This decision follows a positive recommendation from the Committee for Medicinal Products for Human Use and is based on the results of the FLAURA2 Phase III trial. The

This approval marks a significant milestone for the company, indicating that its product is therapeutically equivalent to the reference listed Tibsovo Tablets, 250mg of Servier Pharmaceuticals. Ivosidenib is

The funding will support ongoing clinical trials for X-Linked Retinitis Pigmentosa (XLRP) and advance the company’s Dry Age-related Macular Degeneration (dAMD) programme. The investment round included contributions from